Kamada Ltd. Secures Three-Year Contract worth $25 Million for KAMRAB® and VARIZIG® in Latin America
Rehovot, Israel and Hoboken, N.J., January 22, 2025 – Kamada Ltd. (KMDA), a leading global biopharmaceutical company specializing in rare and serious conditions, announced today the signing of a significant contract with an international organization. This contract grants Kamada the approval to supply KAMRAB® and VARIZIG® in Latin America for the next three years, from 2025 to 2027.
Contract Details
The contract is estimated to generate a total revenue of approximately $25 million for Kamada. The anticipated revenue for the year 2025 has been incorporated into the company’s recently announced 2025 revenue guidance.
Impact on Kamada
This contract marks a significant milestone for Kamada, as it further strengthens the company’s position in the specialty plasma-derived field. With this new agreement, Kamada’s market presence expands to Latin America, opening new opportunities for growth and revenue.
Impact on Consumers and Patients
The availability of KAMRAB® and VARIZIG® in Latin America will provide access to these essential treatments for individuals suffering from rare and serious conditions. KAMRAB® is indicated for the treatment of primary immune deficiency (PI) and hereditary angioedema (HAE), while VARIZIG® is used for the prevention of varicella (chickenpox) in immunocompromised patients and for post-exposure prophylaxis.
Global Market Expansion
- Kamada’s expansion into the Latin American market broadens the reach of its marketed products.
- This move is in line with Kamada’s strategy to target emerging markets and increase its global footprint.
- The success of this contract may pave the way for further international collaborations and partnerships.
Company’s Continued Commitment
Kamada remains dedicated to its mission of developing and commercializing innovative, high-quality therapeutic products for the treatment of various conditions. This contract further solidifies Kamada’s commitment to addressing the needs of patients and healthcare providers worldwide.
About Kamada
Kamada Ltd. is a global biopharmaceutical company focused on the research, development, manufacturing, and commercialization of plasma-derived and recombinant human proteins for the treatment of various conditions. The company’s portfolio includes marketed products for the treatment of rare and serious conditions, such as KAMRAB® for the treatment of primary immune deficiencies and hereditary angioedema, and VARIZIG® for the prevention of varicella (chickenpox) in immunocompromised patients and for post-exposure prophylaxis.
Conclusion
The three-year contract between Kamada and an international organization for the supply of KAMRAB® and VARIZIG® in Latin America is a significant development for the company. This agreement not only represents a substantial revenue opportunity but also signifies Kamada’s continued dedication to addressing the needs of patients and expanding its market presence. The availability of these essential treatments in Latin America will provide access to better healthcare options for individuals suffering from rare and serious conditions. Kamada’s commitment to innovation and growth is evident through its strategic collaborations and partnerships, and this contract is a testament to the company’s ongoing success in the biopharmaceutical industry.
For more information about Kamada and its products, please visit www.kamada.com.
